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Dear Editor,
We appreciate the authors for their interest and 
knowledgeable comments on our study (1). We completely 
agree with them on dividing the geometric mean of brain 
counts by 0.13 since the brain is presumed to receive 13% 
of the cardiac output (2). We have used this score for 
shunt calculation.
The relationship between brain uptake and quantitation of 
the right-to-left (R -L) shunt percentage using technetium-
99m (Tc-99m)-macroaggregated albumin (MAA) whole-
body imaging has been rarely investigated. Ito et al. (3) 
studied 53 patients and found that Tc-99-MAA brain uptake 
could completely distinguish patients with or without 
an R-L shunt and that it could provide complementary 
information and appears promising in predicting clinical 
outcomes.
With our extensive experience in assessing R-L shunting as 
a routine adjunct protocol in a large number of patients 
presenting for ventilation/perfusion single photon emission 
computed tomography scans, in addition to those who are 
only referred for determining the shunt value, we have 
observed that semi-quantitative shunt assessment using 
visual analysis of brain uptake is pragmatic, achievable, 
and associated with a high success rate. Although the 
compelling study by Zhao et al. (4) focused only on 
quantitative analyses, they can test this issue as well.
We agree with Zhao et al. (4) on the important potential 
role of quantitative parameters derived from Tc-99m-
MAA whole-body imaging in computing R-L shunting; 
however, some aspects need more explanation. This 
computation of R-L shunting is not free from limitations 
and might overestimate the true number of patients with 
shunts primarily because of the interference of unbound 
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nuclides of free pertechnetate with uptake in the thyroid, 
salivary glands, and gastric mucosa during whole-body 
imaging. Such radiopharmaceutical impurities associated 
with Tc-99m-MAA may cause fluctuations in the R-L 
shunt percentage. Secondly, there is a logistical limitation 
because this technique requires longer acquisition times 
than brain calculation, especially in busy nuclear medicine 
departments.
Besides, since the majority of the included patients only 
had mild or moderate hepatopulmonary syndrome (HPS), 
the findings cannot be generalized in case of patients with 
severe or very severe HPS. It may bring up a question of 
making a comparison between 2 scintigraphic methods 
in terms of underlying diseases and disease severity in 
different cirrhotic subgroups.
Another point is considering a homogeneous group of 
participants to ensure an accurate comparison between 
studies. In this regard, attention should be paid to porto-
pulmonary hypertension (PoPH) in addition to HPS, which 
is not uncommon in patients with chronic liver disease and/
or portal hypertension. A major pathogenetic mechanism 
in HPS is the dilatation of the pulmonary vasculature, which 
leads to progressive hypoxemia due to intrapulmonary 
shunting. On the contrary, PoPH may be described as 
the obstruction of the arterial flow in the pulmonary 
vascular system in the presence of increased pulmonary 
vascular resistance, which results from high pulmonary 
vasoconstriction (5). Presumably, much smaller particles 
are required to detect R-L shunting in patients with PoPH 
compared to those with HPS (5).
To our knowledge, no clinical studies have performed long-
term follow-up in patients with HPS diagnosed by different 
protocols to address their clinical outcomes. We believe 
that the question would be better answered by future 
clinical research aiming at evaluating outcomes according 
to shunt severity, based on methods ideally offering a 
more comprehensive profiling to individualize patient 
management.
Moreover, we would welcome future research specifically 
aimed at establishing or validating imaging methods for 
assessing HPS in patients without cirrhosis who have a 
better prognosis (6). Another research area is to establish or 
validate imaging methods to address the treatment efficacy 
or accurately predict outcomes. Such research would 
indeed be useful to clinicians when they are considering 
shunt assessment assuming that brain uptake can facilitate 
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